George Clinical’s largest hub outside the head office of Sydney, offering full CRO services and a site network that spans the country.

George Clinical In China

China is George Clinical’s largest hub outside the head office of Sydney, offering full CRO services and a site network that spans the country.

With its large potential for patient recruitment and a rapidly growing pharmaceutical market, China – currently the third largest in the world, is an obvious choice for many when entering the Asian market.

The Chinese healthcare delivery system consists of public hospitals and community healthcare centres, with an increasingly private care system. Recent CNDA changes in the regulatory environment have re-inforced the need for quality data to be both verifiable and transparent with an increasing acceptance of ICH GCP standards. A complete overhaul of the regulatory process in July 2018 was undertaken to encourage innovation and shorten CTA approval times to 4-6 months. Additionally, truly innovative molecules may also apply for expedited approval shortening CTA approval times to as little as 2 months. A similar overhaul of the registration process has also been undertaken for medical devices and IVD products. These changes are significant and make China an increasingly attractive destination for trials.

George Clinical has been conducting clinical trials in China since 2007 with an extensive network of over 260 trial centres in 60 cities for Phase II-IV trials, and a wider network that includes community health centres in semi-urban and rural areas for Phase IV trials.

What are the benefits of conducting clinical trials in China?

  • China has access to a large patient pool
  • Potential for treatment naïve patients, especially in oncology
  • Rapidly developing medical infrastructure in urban centres and centres of excellence for many common diseases such as hypertension, diabetes, oncology, and renal disease
  • Lower operational costs

What are the most prevalent diseases in China?

  1. Stroke
  2. Ischaemic heart disease
  3. Chronic obstructive pulmonary disease
  4. Cancers
  5. Road injury
  6. Hypertension
  7. Diabetes mellitus
  8. Lower respiratory infections

Our People in China are Experienced in

Cardiovascular 48%

Central Nervous System 33%

Medical Devices 33%

Endocrinology 48%

Oncology 35%

Respiratory 43%

Nephrology 23%

Clinical Development Phase – China


George Clinical Address:
Level 18, Tower B, Horizon Tower
Haidian District
Beijing, 100088
P.R. China
Phone: +86 10 8280 0476

2223, 22/F Tomson Commercial Building,
710 Dongfang Road, Pudong District
Shanghai, 200122
P.R. China


Population 1.4 billion
Number of Personnel 60
Official Language Putonghua (Mandarin). Local dialects may be used
Hospital Records Language Simplified Chinese
Electronic Hospital Records Electronic records are used but not standardised across different provinces in China.
In-country services

Project Management, Clinical Operations, Data Management, Medical and Safety Services, Clinical Compliance, Regulatory Services, Statistics, Health Economics

Clinical Operations

Project Management, Clinical Operations

Clinical Operations

Clinical Operations

Clinical Operations

Clinical Operations

Clinical Operations

Clinical Operations

GDP – per capita (US $) $14,100
Health Expenditures 5.6% of GDP 
George Clinical

Profits from George Clinical support the work of The George Institute for Global Health.

Join our Mailing List

Add George Clinical to your network